Product approval information is indicated for:
• Replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients two years of age or older.
• Maintenance therapy to improve muscle strength and disability in adult patients with Multifocal Motor Neuropathy (MMN).
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/ZrkCJwx
No comments:
Post a Comment